Dihexa Doses Used in Published Studies: What Researchers Reported

What this page covers

The phrase most often typed into search engines about this compound is some version of "dihexa subcutaneous dosage." This page does not answer that as an instruction, and it does not contain a dosing chart. Instead, it describes what the published literature indexed in PubMed actually administered: which species were studied, which routes of administration were described, what model or endpoint the work used, and what researchers reported as an outcome. Each statement is placed next to its citation so readers can check the primary source themselves.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, and no amount mentioned or omitted should be read as a suggestion for use in a person.

What dihexa is in the published literature

Dihexa is described in the literature as a metabolically stabilised analog of angiotensin IV. A 2013 pharmacology paper evaluated metabolically stabilised angiotensin IV analogs as procognitive and antidementia candidates in animal models, and framed the compounds as small molecules designed to resist enzymatic breakdown better than the parent peptide sequence (PMID 23055539). Two review articles from the same research programme placed these analogs in a mechanistic context: one described the development of small-molecule angiotensin IV analogs as candidate treatments for Alzheimer's and Parkinson's diseases (PMID 25455861), and the other described the brain hepatocyte growth factor (HGF)/c-Met receptor system as the proposed target through which such analogs were thought to act (PMID 25649658).

That framing matters for a dosing question. The published work treats dihexa as an experimental probe of a receptor system in animals, not as a product with an established human dose range. Readers looking for a number are looking for something the cited literature has not produced.

Administration in published studies, report by report

Rodent pharmacology of stabilised angiotensin IV analogs (2013)

The 2013 study in The Journal of Pharmacology and Experimental Therapeutics evaluated metabolically stabilised angiotensin IV analogs, including dihexa, for procognitive and antidementia activity in laboratory animals (PMID 23055539). Researchers reported the work as an evaluation of candidate compounds in rodent behavioural and pharmacological testing rather than as a dose-ranging safety study. The publicly indexed summary of that study emphasises metabolic stability and activity in animals; this page therefore does not reproduce milligram figures buried in the full-text methods, because an amount stripped of its vehicle, species, strain, route and endpoint conveys nothing useful and is easily mistaken for a recommendation.

APP/PS1 transgenic mouse study (2021)

A 2021 report in Brain Sciences examined dihexa in the APP/PS1 mouse, a transgenic model of amyloid pathology, and researchers reported that the analog was associated with improved performance on memory testing and implicated PI3K/AKT signalling as the pathway involved (PMID 34827486). The species in that study was the mouse and the outcome measures were behavioural and molecular. Nothing in that report establishes a human amount, a human route, or a duration of administration for a person.

Rat 3-nitropropionic acid model of Huntington's-like symptoms (2024)

A 2024 study in the Journal of Huntington's Disease examined the effects of an angiotensin IV analog in rats treated with 3-nitropropionic acid to produce Huntington's-disease-like symptoms (PMID 38489193). The study design was a toxin-induced rodent disease model with a comparison to untreated animals, and researchers reported it as an evaluation of effects in that model. Again the species was the rat, and the reported purpose was mechanistic and exploratory rather than a translation of an amount into clinical practice.

Fish lateral line hair-cell study (2015)

A 2015 paper in Frontiers in Cellular Neuroscience reported that an HGF mimetic protected lateral line hair cells from aminoglycoside exposure in an aquatic whole-animal model (PMID 25674052). This is a useful example of why "dosage" is the wrong frame for much of this literature: in that experimental system the compound was studied at the level of an in vivo aquatic preparation and a cellular endpoint, not as a weight-based injection into a mammal. A concentration in an experimental medium and a subcutaneous amount in a person are not interchangeable quantities.

Systematic review of angiotensin IV cognitive studies (2018)

A 2018 systematic review in Neuroscience and Biobehavioral Reviews collected experimental studies of the cognitive effects of angiotensin IV and angiotensin-(1-7) (PMID 29733881). As the title of that review states, the body of evidence it assembled was experimental, and researchers reported cognitive benefits across the experimental studies reviewed. A review of experimental studies is a map of what animals and preparations were tested; it is not a clinical dosing source.

Summary of what the cited reports specify

On the specific search for a subcutaneous amount

None of the reports cited on this page described a subcutaneous dose of dihexa in humans, and none described a human dose-finding or safety trial. The routes and systems that appear in the cited work are rodent administration in pharmacology and disease-model studies (PMID 23055539, PMID 38489193) and an aquatic whole-animal preparation (PMID 25674052). One of the design points emphasised in the review literature is that these small-molecule analogs were engineered for metabolic stability and brain access in animal models (PMID 25455861) — a chemistry goal, not a validated human route.

When a search phrase implies that a number exists, the honest summary is that the indexed literature does not supply one for human use. A figure circulating outside the peer-reviewed record has no citation behind it, and this page will not supply one either.

Why experimental amounts do not convert into a recommendation

Several structural reasons explain the gap between an animal experiment and a person, and none of them depend on opinion:

• Species and model specificity. An amount that produced a measurable change in APP/PS1 transgenic mice (PMID 34827486) or in rats given a mitochondrial toxin (PMID 38489193) is tied to that animal's physiology and to the artificial lesion used to create the deficit.
• Route and formulation. Concentrations in an aquatic or cell-level preparation (PMID 25674052) are not weight-based doses, and the vehicle, purity and delivery method all change exposure.
• Endpoint choice. The endpoints in the cited work were behavioural performance and signalling markers (PMID 34827486), not patient-relevant clinical outcomes.
• Evidence stage. The systematic review that assembled this field described an experimental evidence base (PMID 29733881), meaning no dose has been tested against placebo for efficacy and safety in people.
• Field-level caution about peptide enthusiasm. A 2026 review of therapeutic peptides in orthopaedics discussed applications alongside challenges and future directions, and researchers there framed clinical translation as an open problem rather than a settled one (PMID 41490200).

Effects and Adverse Events in Dihexa Research: What Studies Report

The cited animal reports were designed around efficacy and mechanism rather than toxicology. Researchers reported cognitive improvement in a transgenic mouse model along with PI3K/AKT pathway involvement (PMID 34827486), protection of hair cells from aminoglycoside-induced damage in a fish model (PMID 25674052), and cognitive benefits across the experimental studies gathered in a systematic review of angiotensin IV and angiotensin-(1-7) (PMID 29733881). The angiotensin IV analog study in the rat Huntington's-like model was likewise reported as an evaluation of effects in that model (PMID 38489193).

What the cited record does not contain is a human adverse-event profile: no dose-limiting toxicity data, no long-term exposure data in people, and no organ-system safety monitoring in a clinical population. A proposed mechanism that involves growth-factor signalling through the HGF/c-Met system (PMID 25649658) is biologically consequential, and the absence of human safety data in the cited reports is a gap rather than a reassurance.

Regulatory context

Dihexa is not an approved drug product. Material of this kind is typically distributed and labelled for research use only, which means it has not undergone the review that establishes a dose, an indication, a route or a safety profile for people. Reviews of therapeutic peptides have discussed exactly this tension between interest and regulatory readiness (PMID 41490200). This paragraph is general regulatory background and is not legal advice.

Open questions in the published record

1. Whether any human pharmacokinetic profile exists for the compound; the cited literature is animal and review work (PMID 29733881).
2. Whether findings in an amyloid-overexpressing mouse model track with human disease outcomes, since the reported endpoints were model-specific behaviour and signalling (PMID 34827486).
3. How activity across different systems — rodent brain, rat toxin model, fish sensory epithelium — relates to a single mechanism proposed at the HGF/c-Met receptor (PMID 25649658, PMID 25674052).
4. Whether the metabolic-stability and brain-access design goals described in the review literature hold in humans (PMID 25455861).

Readers who came here for a chart will leave without one, and that is the accurate reflection of the literature rather than an omission. Again: this page is educational only and is not medical advice; questions about any substance belong with a licensed physician.

References

• Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents (The Journal of Pharmacology and Experimental Therapeutics, 2013)
• AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway (Brain Sciences, 2021)
• Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats (Journal of Huntington's Disease, 2024)
• Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure (Frontiers in Cellular Neuroscience, 2015)
• Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies (Neuroscience and Biobehavioral Reviews, 2018)
• The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases (Progress in Neurobiology, 2015)
• The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease (Journal of Alzheimer's Disease, 2015)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)